![Professor Anne Kiltie Professor Anne Kiltie](/img/200x200/staffpages/uploads/s03ak1/avatar/p7BCQfAeEtKAoM2ZOkxiWhQaMFIA9SeQGKnOC1A7.png)
MA DM DSc MRCP(UK) FRCR
Friends of ANCHOR Clinical Chair in Oncology
- About
-
- Email Address
- anne.kiltie@abdn.ac.uk
- Office Address
Room 5.053
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
I qualified in medicine from the Universities of Cambridge and Oxford and trained in Clinical Oncology at the Christie Hospital, Manchester, and Cookridge Hospital, Leeds. I undertook my DM at the Paterson Institute, University of Manchester and was a Clinical Research Fellow at ICRF Clare Hall before taking up a Senior Lecturer/Honorary Consultant Clinical Oncologist appointment at the University of Leeds in 2001. I moved to the Department of Oncology, University of Oxford in 2009, and obtained my DSc and personal chair in 2016.
I took up my appointment as Friends of ANCHOR Clinical Chair of Oncology at the University of Aberdeen in June 2021.
My research focusses on exploiting dietary fibre manipulation and its effects on the gut microbiome as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.
Qualifications
- DSc Medical Sciences2016 - University of Oxford
- DM Medical Sciences1999 - University of Oxford
- BM BCh Medicine1988 - University of Oxford
- BA Medical Sciences1985 - University of Cambridge
- MRCP(UK) General Medicine1992 - Royal College of Physicians of England
- FRCR Clinical Oncology1995 - Royal College of Radiologists
- MA Medicine1989 - University of Cambridge
- MA Medicine1999 - University of Oxford
Memberships and Affiliations
- Internal Memberships
-
Jul 2021 - present Member of the Rowett Institute Ethics Panel
Oct 2021 - present Member of Friends of ANCHOR Research Advisory Group
- External Memberships
-
Apr 2024 - present Chair, Scottish Radiation Research Forum (ScoRRF)
Jun 2023 - present Member of RAIDER TrialTranslational Working Group
Jan 2022 - present Member of Scientific Review Group BCAN Bladder Cancer Research Innovation Award 2022
Jan 2022 - present Member of Scottish Radiotherapy Research Forum Committee
Oct 2018 - present Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Research Network Management Committee
Dec 2017 - present Member of Editorial Board of European Urology Oncology
Oct 2016 - present Associate Editor of Bladder Cancer
2014 - present Grant reviewer for Italian Association for Cancer Research (AIRC)
Sept 2012 - present British Uro-oncology Group Executive Committee Trustee
Jan 2012 - present Royal College of Radiologists representative on Advisory Appointments Committees
- Research
-
Research Overview
Tumours in the pelvis, including bladder, prostate and colorectal cancer and gynaecological cancers may be treated by surgical removal or organ-preserving radiotherapy-based treatments. Current organ-preservation standard of care for most tumour sites includes addition of radiosensitising chemotherapy to improve tumour control. However, this often comes at the expense of increased radiotherapy-induced side effects to the surrounding normal tissues, including the intestines. Furthermore, such combined treatments are often not tolerated by elderly patients. With the proportion of over 75-year olds set to double by 2050, there is an urgent need to find alternative approaches to radiosensitisation.
Having worked on histone deacetylase inhibitors, which we showed to be effective tumour radiosensitisers without additional acute and late small intestinal toxicity in in vivo models, we are now working to exploit dietary fibre manipulation and the gut microbiome as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.
Research Areas
Applied Health Sciences
Biomedical Sciences
Nutrition and Health
Research Specialisms
- Medicine
- Food Science
- Bacteriology
- Oncology
Our research specialisms are based on the Higher Education Classification of Subjects (HECoS) which is HESA open data, published under the Creative Commons Attribution 4.0 International licence.
Supervision
Supervisees
- MS MEREL VAN DEN HAAK
- MR ADAM POTTER
- MR DANIEL SESCU
- MISS ANAM WAJID
- Teaching
-
Teaching Responsibilities
ME3013 MBChB SSC2: supervisor
BM4501 BSc Honours project: supervisor
RN5504 Nutrition and Health through the Life Stages: lecture
RN5505 Clinical Nutrition: lecture and seminar
RN5503 Clinical Nutrition for Disease Prevention: lecture
Non-course Teaching Responsibilities
I am a Regent for the MB ChB Regent Scheme.
- Publications
-
Page 6 of 10 Results 51 to 60 of 96
Using gene polymorphisms to assess bladder cancer risk: Progress and challenges
Journal of Urology, vol. 187, no. 2, pp. 379-380Contributions to Journals: Editorials- [ONLINE] DOI: https://doi.org/10.1016/j.juro.2011.11.002
- [ONLINE] View publication in Scopus
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene
Human Molecular Genetics, vol. 20, no. 21, pp. 4268-4281Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1093/hmg/ddr303
- [ONLINE] View publication in Scopus
Radiotherapy for node positive penile cancer: Experience of the leeds teaching hospitals
Journal of Urology, vol. 186, no. 2, pp. 524-529Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.juro.2011.03.117
- [ONLINE] View publication in Scopus
Functional assays to determine the significance of two common XPC 3'UTR variants found in bladder cancer patients
BMC Medical Genetics, vol. 12, 84Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1186/1471-2350-12-84
- [ONLINE] View publication in Scopus
In vitro functional effects of XPC gene rare variants from bladder cancer patients
Carcinogenesis, vol. 32, no. 4, pp. 516-521Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1093/carcin/bgr005
- [ONLINE] View publication in Scopus
Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer
Journal of Clinical Oncology, vol. 29, no. 6, pp. 733-738Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1200/JCO.2010.31.5721
- [ONLINE] View publication in Scopus
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci
Nature Genetics, vol. 42, no. 11, pp. 978-984Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/ng.687
- [ONLINE] View publication in Scopus
MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer
Cancer Research, vol. 70, no. 18, pp. 7017-7026Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1158/0008-5472.CAN-10-1202
- [ONLINE] View publication in Scopus
Common predisposition alleles for moderately common cancers: Bladder cancer
Current Opinion in Genetics and Development, vol. 20, no. 3, pp. 218-224Contributions to Journals: Review articles- [ONLINE] DOI: https://doi.org/10.1016/j.gde.2010.01.002
- [ONLINE] View publication in Scopus
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer
Nature Genetics, vol. 42, no. 5, pp. 415-419Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/ng.558
- [ONLINE] View publication in Scopus